All Posts
CMC Documentation Required for a Pre-IND Briefing Package for a Novel Biologic
A pre-IND meeting is one of the highest-leverage interactions a biologics sponsor will have with
June 9, 2026
A pre-IND meeting is one of the highest-leverage interactions a biologics sponsor will have with
When a pharmaceutical or life sciences company receives a Form 483, Warning Letter, or Consent
The Critical Bridge in Drug Development Technology transfer stands as one of the most pivotal—yet
Good Manufacturing Practice (GMP) is the lifeblood of the pharmaceutical industry. It is the minimum
In the modern drug development world, the transition from clinical phases to commercial viability is
The intersection of Artificial Intelligence and drug development reached a fever pitch on January 14,
The FDA’s January 2026 announcement on “Flexible Requirements for Cell and Gene Therapies” has sent
Developing a therapeutic from lab to commercial launch requires much more than scientific innovation. it
In many industries, a manufacturing defect means a returned product and a frustrated customer. In
If the pharmaceutical landscape of 2025 was defined by resilience, 2026 is defined
Start building reliable, high-quality drug development programs today.